
Venture capital · Early stage
Invivo Partners
Barcelona-based venture firm investing in early-stage biotech and AI-driven deeptech companies, mainly European with an emphasis on Spain, run by three founding partners and backed by public and private investors.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Invivo Partners right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (ESMA register).
Latest investments
Rounds Invivo Partners joined, from press and the firm’s own posts.
Every round Invivo Partners joined
Round sizes, Invivo Partners’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company Invivo Partners backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Invivo Partners
Events where Invivo Partners’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Invivo Partners is based in Barcelona, Spain. Its registered address is PASEO DE GRACIA 54, 2º D BARCELONA BARCELONA 08007.
5 fund vehicles are on public registers (ESMA register), including INVIVO VENTURES III PARALLEL FUND, FCRE, S.A., INVIVO VENTURES III PARALLEL FUND, FCRE, S.A. and INVIVO VENTURES III, FCRE.
Stages: Pre-seed, Seed, Series A. Sectors: Biotech, Life sciences, AI, Deep tech and hardware, Robotics, Space, Mobility, Climate and energy. From the firm’s own website.
Seeks biotech with convincing animal-model evidence and first-in-class potential, plus AI-driven deeptech aimed at real problems, mostly in healthcare. Wants disruptive platforms, a clear roadmap and budget, committed multidisciplinary teams, room to extend into related applications and strong IP barriers. Enters at pre-seed, seed or Series A and adds follow-on capital as milestones are reached. From the firm’s own website.
€2M to €4M per investment, according to the firm’s own website.
Invivo Partners lists 18 portfolio companies on its website, including Minoryx Therapeutics, Sanifit Therapeutics, nLife Therapeutics, Peptomyc and Versantis.
Firms whose websites list some of the same companies include Columbus Venture Partners, AdBio and AMR Action Fund.
Know before Invivo Partners’s next round is announced.
PRO tracks Invivo Partners’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.